Vyvanse and Cardiac Risk
For patients without known cardiac disease or risk factors, Vyvanse can be safely initiated after a thorough cardiac-focused history and physical examination, without requiring routine ECG or cardiology consultation. 1
Key Cardiac Risks
Vyvanse (lisdexamfetamine) carries specific cardiovascular warnings that must be understood:
- Sudden cardiac death has been reported in patients with structural cardiac abnormalities or serious cardiac disease treated with CNS stimulants at recommended ADHD dosages 2
- Blood pressure and heart rate increases are expected: mean increases of 2-4 mmHg (systolic and diastolic BP) and 3-6 bpm (heart rate), with some patients experiencing larger increases 2, 3
- These hemodynamic changes are sustained over time and persist with chronic use 3
Pre-Initiation Cardiac Assessment
Required History Elements
Obtain a cardiac-focused history that specifically screens for 1:
- Personal history of chest pain, dyspnea, palpitations, near-syncope, or syncope (especially with exertion)
- Known structural heart disease, cardiomyopathy, or arrhythmias
- Family history of sudden cardiac death (particularly in young relatives)
- Current medications that may interact or prolong QT interval
Physical Examination
- Baseline blood pressure and heart rate measurement
- Cardiac auscultation for murmurs or abnormal rhythms
When ECG is NOT Needed
Routine ECG screening before initiating Vyvanse is not recommended when history, family history, and physical examination are normal 1. The evidence does not support routine ECG screening, and it may lead to inappropriate discontinuation of beneficial treatment due to incidental findings of unclear significance 1.
Absolute Contraindications
Do not prescribe Vyvanse in patients with 2, 4:
- Known structural cardiac abnormalities
- Cardiomyopathy
- Serious cardiac arrhythmias
- Coronary artery disease
- Other serious cardiac disease
When to Consult Cardiology
Cardiology consultation is indicated when 1:
- Newly identified cardiac risk factors are discovered during screening (regardless of whether ADHD medication will be prescribed)
- Known congenital heart disease or arrhythmias exist—though these patients should already be under cardiology care, and the cardiologist may recommend additional investigation or specialized surveillance before starting therapy
- Cardiac symptoms emerge during treatment (chest pain, syncope, palpitations)
Important caveat: For typical ADHD patients without cardiac disease or risk factors, there is no evidence supporting routine cardiology consultation before starting Vyvanse 1.
Ongoing Monitoring
Blood Pressure and Heart Rate
- Monitor blood pressure and heart rate at each follow-up visit 2
- Be vigilant for tachycardia and hypertension development 2
Warning Signs Requiring Immediate Evaluation
Instruct patients to contact you immediately if they develop 2:
- Exertional chest pain
- Unexplained syncope
- Severe palpitations
- Any symptoms suggestive of cardiac disease
Real-World Safety Data
Recent population-based evidence provides reassurance about cardiovascular safety:
- A large Danish/Swedish cohort study found no increased risk of major adverse cardiovascular and cerebrovascular events (MACE) in lisdexamfetamine users compared to users of other ADHD medications (pooled IRR 1.10,95% CI 0.77-1.58) 5
- Analysis of over 2 million ADHD medication initiators showed heart failure/cardiomyopathy rates in patients under 44 years were less than 50 per 10,000 person-years, with no clear trends by duration of use 6
- The highest cardiac event rates occurred in elderly patients (≥65 years) soon after treatment initiation, likely reflecting unmasking of pre-existing disease rather than drug causation 6
Clinical Algorithm
- Screen with cardiac-focused history and physical examination
- If normal → Initiate Vyvanse without ECG or cardiology consultation
- If cardiac risk factors identified → Cardiology consultation before initiating
- If known cardiac disease → Discuss with patient's cardiologist; individualize decision
- Monitor BP/HR at all follow-ups
- Educate patient about warning symptoms requiring immediate contact
This approach balances the documented cardiovascular effects of amphetamines 3 with guideline recommendations against over-screening 1 and real-world safety data showing low absolute risk in appropriately selected patients 5, 6.